August 27), Huaxi Biotech announced its results for the first half of 2026:

During the period, revenue was 1.756 billion yuan, down 22.32% year-on-year; net profit attributable to the parent company was 153 million yuan, down 30.82% year-on-year; and non-net profit attributable to the parent company was 129 million yuan, down 25.49% year-on-year.

Huaxi Bio's performance list for the first half of the year, cut from the announcement

This is the third consecutive year that Huaxi Bio has seen revenue and net profit double decline in the mid-term newspaper.

As of yesterday's close, Huaxi biological total market value 17.32 billion yuan, In recent years accumulated decline 32.31%, Market value evaporation about 8.267 billion yuan.

Skin care business declines by more than 50%

In the past four years, Huaxi Biotech's performance has shown a continuous decline.

In 2022, Huaxi Biotech's revenue and parent net profit reached historical peaks of 6.359 billion yuan and 971 million yuan respectively. Since then, they have declined year by year, and have dropped to 4.199 billion yuan and 292 million yuan respectively by 2025. Between 2023 and 2025, both indicators experienced double-digit declines for two years.

A summary of Huaxi Biotech's performance in the past 6 years is obtained from Oriental Fortune. com

Entering the first half of 2026, the decline has not changed. Revenue fell 22.32% year-on-year to 1.756 billion yuan, and net profit attributable to the parent company fell 30.82% year-on-year to 153 million yuan.

Looking at different business sectors, the performance of each line is significantly differentiated.

The raw materials business achieved revenue of 638 million yuan in the first half of the year, a year-on-year increase of 1.87%, accounting for 36.38% of the main business income. Among them, the international market performed well, with revenue reaching 344 million yuan, a year-on-year increase of 4.05%, and the proportion increased to 54.06%. Emerging markets such as South America, Eastern Europe, and Southeast Asia grew well, and the international revenue growth rate of dermatological science materials exceeded 15%.

The medical terminal business achieved revenue of 599 million yuan in the first half of the year, accounting for 34.15% of the main business income. Among them, skin medical products achieved revenue of 426 million yuan, the internal product structure continued to be optimized, and the sales of the third category of medical device products were approximately 4.28 million, a year-on-year increase of approximately 85%.

Although the nutrition science innovation and transformation business is small in size, it is growing rapidly. In the first half of the year, revenue reached 61 million yuan, a year-on-year increase of 59.71%.

However, the dermatology innovation and transformation business (formerly functional skin care products business) performed poorly, achieving revenue of 448 million yuan in the first half of the year, a year-on-year decrease of 50.88%, and its proportion in total revenue dropped to 25.53%.

It is worth noting that while revenue is under pressure, Huaxi Biotech's expense structure has undergone positive changes: sales expenses fell by 25.84% year-on-year, while the R & D expense ratio increased to 12.07%, an increase of 1.85 percentage points over the same period last year. During this decline and rise, Huaxi Biotech's intention to actively transform from scale expansion to quality growth is very obvious. It is trying to reshape its long-term competitiveness by increasing investment in R & D and optimizing product structure.

Deep adjustment in six dimensions

Under pressure from performance, Huaxi Biotech launched systematic iterative upgrades around six dimensions in the first half of the year, striving to reshape the growth base through in-depth adjustment.

The first is to promote organizational change. Guided by the development trend of life science and technology, we will promote the transformation of the organizational model from traditional business collaboration to an agile, efficient and open scientific and technological innovation organization, laying a solid management foundation for long-term competition.

The second is scientific research and transformation of results. Its 3 national key R & D plans and 1 provincial talent project have passed acceptance, continued 6 national and provincial and municipal key scientific research projects, and continued to promote the upgrading and industrialization of biomanufacturing technology.

The third is to promote the implementation of the strategic layout of synthetic biology and promote the launch of new raw materials products. In the first half of the year, a total of 5 bioactive raw materials and 1 solution product were launched, covering medicine, skin care, nutrition and other fields.

The fourth is to face new production capacity and new platform layout in the future. The Tianjin Pilot Platform was selected into the national-level cultivation list and undertook 40 internal and external projects; the Dongying Sterile Sodium Hyaluronate Workshop obtained production license and Japan AFM certification.

The fifth is to accelerate digital and intelligence integration innovation. Optimize processes and information systems, and put the first phase of the enterprise resource planning system into operation; improve data governance and business analysis kanban; upgrade the "Xi AI Intelligent Employee Center" to promote the application of AI in knowledge management, R & D support and other scenarios.

The sixth is to improve ESG management. Its CDP rating has been upgraded to A-(climate) and A (water security), and its EcoVadis rating has been upgraded to silver; it has promoted carbon accounting and clean energy substitution and obtained ISO environmental and energy certification; a supplier ESG management system has been built to strengthen green supply chain construction.

Future bets on "regeneration" track

According to the investor relations activity record released by Huaxi Biotech on July 30, it focuses on its strategic layout in the field of regenerative medical beauty.

On July 28, South Korea's VAIM GLOBAL polylactic acid facial filler JUVELOOK, represented by Huaxi Biotech, was officially approved for marketing by the State Food and Drug Administration (NMPA)(Registration Certificate No.: State Machinery Note I 20263130274).

This is not only a key step for Huaxi Biotech in the field of regenerative medical beauty, but also an important milestone in its continuous improvement of its product matrix around extracellular matrix (ECM) aging intervention.

In terms of product richness, based on existing products such as hyaluronic acid fillers, compliant water and light products, and compliant kinetic elements, the introduction of JUVELOOK further expands Huaxi Biotech's product portfolio in the field of ECM aging intervention, and is expected to form a more complete combination treatment solution with existing products.

It is reported that JUVELOOK was launched in South Korea in 2014 and has so far entered more than 60 countries and regions around the world, with cumulative sales of more than 3 million bottles. It has a solid foundation for international market verification. Preparations for the domestic launch of this product have started and are expected to be officially launched on the market in October 2026.

In terms of channels, Huaxi Biotech will rely on a commercial system covering about 8000 medical beauty institutions across the country to promote the introduction of core institutions, key doctor training and regional market layout in stages, and formulate clinical application and joint treatment plans based on product characteristics, and gradually establish JUVELOOK's professional recognition and long-term brand value in the regenerative medical beauty market in China.

At the same time, Huaxi Biotech disclosed in its financial report in the first half of the year that it will continue to strengthen research on recycled materials and develop safer and more effective recycled medical beauty products. Relevant products have completed design verification and entered the stage of system performance evaluation and biosafety evaluation.

At the strategic level, Huaxi Biotech has recently established a number of new professional operating entities. Among them, Huaxi Youth (Beijing) focuses on the R & D and sales of AI and intelligent robots; Huaxi Biointelligent Manufacturing (Tianjin) covers the production of drugs, cosmetics, and medical devices. and manufacturing of bio-based materials; Huaxihui (Xining) arranges health consulting, cosmetics wholesale and health care services.

From the contraction of functional skin care products business to the continued increase in emerging tracks such as regenerative medical beauty and nutritional science, Huaxi Biotech is undergoing a structural change from the inside out.

However, transformation has never been an easy journey-between the decline of established businesses and the cultivation of emerging sectors, there is still a double test of time and market.

However, what is certain is that Huaxi Biotech is betting on a broader future.

This article explores Aromatherapy, fragrance, perfume, essential oil, non-fire aroma, aroma candle, rattan aroma, home aroma, natural aroma, diffuser, sharing the latest industry insights and offering practical references for enthusiasts.

Source: 品观网 (https://www.pinguan.com/)

This article is reproduced from the original source for information sharing only. If it infringes any copyright, please contact us and we will remove it promptly.

© 2026 CeresMall | www.CeresMall.com